Search our Database of Scientific Publications and Authors

I’m looking for a

    11112 results match your criteria Cutaneous T-Cell Lymphoma

    1 OF 223

    (18)F-fluorodeoxyglucose-positron emission tomography is more sensitive than computed tomography in initial staging of patients with an anaplastic T-cell lymphoma first presenting in the skin.
    Eur J Dermatol 2017 Jul 19. Epub 2017 Jul 19.
    Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France.
    Background: The role of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) in the evaluation of anaplastic large-cell lymphoma (ALCL) first presenting in the skin is not well established, while computed tomography (CT) is used as a standard procedure.

    Objectives: The aim of this study was to evaluate the use of FDG-PET versus CT at initial staging of ALCL first presenting in the skin.

    Materials & Methods: Eleven cases of ALCL first presenting in the skin who underwent both FDG-PET and CT were retrospectively analysed. Read More

    Primary Cutaneous Small/Medium CD4+ T-CELL Lymphoproliferative Disorder Occurring in a Patient With Metastatic Melanoma.
    Am J Dermatopathol 2017 Jul 14. Epub 2017 Jul 14.
    *Department of Pathology, University of Virginia Medical Center, Charlottesville, VA; †Division of Hematology and Oncology, Department of Medicine, University of Virginia Medical Center, Charlottesville, VA; and ‡Dermatology PLC, Charlottesville, VA.
    Therapeutic agents designed to stimulate the immune system are now cornerstones in the treatment of metastatic melanoma. These drugs promote lymphocyte growth and survival, which could plausibly result in clinical lymphoproliferative disorders. We report the case of a 62-year-old female with metastatic melanoma who developed primary cutaneous small/medium CD4 T-cell lymphoproliferative disorder (PC-SMTCL) after treatment with vemurafenib and recombinant high-dose interleukin-2 (IL-2). Read More

    Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report.
    J Cutan Med Surg 2017 Jul 1:1203475417721425. Epub 2017 Jul 1.
    2 Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    We present the extraordinary case of a 72-year-old man with a history of primary cutaneous peripheral T-cell lymphoma not otherwise specified (pcPTCL-NOS) previously controlled with topical agents who developed tumours in a sporotrichoid pattern. Culture of the tumours was negative, and histopathology showed findings consistent with recurrent pcPTCL. The tumours were successfully treated with localised radiation therapy. Read More

    Characteristics And Outcomes Of Anaplastic Large Cell Lymphoma Patients-A Single Centre Experience.
    J Ayub Med Coll Abbottabad 2017 Jan-Mar;29(1):37-41
    Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
    Background: Anaplastic large cell lymphoma (ALCL) is the second most common T cell lymphoma and 2% of all non-hodgkin lymphoma (NHL). It is an aggressive lymphoma with three subtypes, primary cutaneous ALCL, primary systemic ALK +ve ALCL and primary systemic ALK-ve ALCL depending upon rearrangement of Anaplastic Lymphoma Kinase (ALK) gene into ALK +ve and ALK -ve ALCL. Purpose of study is to determine the outcome of patients with ALCL treated at our institute. Read More

    Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma.
    Cell Immunol 2017 Jul 10. Epub 2017 Jul 10.
    Washington University School of Medicine, St Louis, MO 63110, USA. Electronic address:
    CD28 is the major costimulatory receptor on T cells regulating proliferation, survival and effector function. Acquired mutations in the extracellular domain of CD28 have been identified in patients with cutaneous T cell lymphoma, angioimmunoblastic T cell lymphoma and other T cell neoplasms, suggesting it may contribute to disease pathogenesis. We used a heterologous system in which mutant human CD28 was expressed on primary murine T cells deficient in CD28 to ascertain how specific mutations identified in a genetic screen of patients with cutaneous T cell lymphoma affected normal T cell function. Read More

    Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study.
    J Am Acad Dermatol 2017 Jul 11. Epub 2017 Jul 11.
    University of Alberta, Edmonton, Canada; Department of Dermatology, University of Copenhagen, Copenhagen, Denmark.
    Background: Classic Sézary syndrome (SS) is defined by erythroderma, generalized lymphadenopathy, and leukemic blood involvement. Clinical observations suggest that SS begins as a nonerythrodermic disease.

    Objective: To describe the early clinical characteristics of patients with SS. Read More

    Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat - How shall we treat? A review of the literature.
    Br J Dermatol 2017 Jul 13. Epub 2017 Jul 13.
    Department of Dermatology, Venerology, Allergology and Phlebology, Johannes Wesling Medical Centre, University Hospital of Ruhr-University Bochum, Germany.
    Brentuximab vedotin is an antibody-drug conjugate that brings the antimicrotubule agent monomethyl auristatin E into CD30-expressing cells. Some prior studies could demonstrate good efficacy in cutaneous lymphomas. The standard therapeutic scheme is 1. Read More

    Possible role of Helicobacter pylori in diseases of dermatological interest.
    J Biol Regul Homeost Agents 2017 07 13;31(2 Suppl. 2). Epub 2017 Jul 13.
    Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
    Helicobacter pylori is a gram-negative, flagellate, microaerophilic bacterium identified for the first time about 30 years ago, as a pathogenic factor of gastritis and peptic ulcer. Soon after, it was linked to several gastrointestinal and extra-gastrointestinal diseases (hematological, cardiovascular, neurological, pulmonary and ocular diseases, obesity, diabetes mellitus, growth retardation and extragastric MALT lymphoma). Association and possible cause-effect correlation with H. Read More

    Anaplastic large cell lymphoma: A great mimic on cytology.
    J Cytol 2017 Jul-Sep;34(3):165-167
    Department of Pathology, Seth GS Medical College and King Edward Memorial Hospital, Mumbai, Maharashtra, India.
    Anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma, accounting for <5% of non-Hodgkin's lymphoma. Cutaneous involvement can be primary or secondary arising in systemic ALCL. The diagnostic feature in both is the presence of pleomorphic, CD30 positive hallmark cells. Read More

    ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.
    Oncotarget 2017 Jun 27. Epub 2017 Jun 27.
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Cutaneous T-cell lymphomas (CTCLs) are extremely symptomatic and still incurable, and more effective and less toxic therapies are urgently needed. ONC201, an imipridone compound, has shown efficacy in pre-clinical studies in multiple advanced cancers. This study was to evaluate the anti-tumor activity of ONC201 on CTCL cells. Read More

    HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL.
    Cancer Cell 2017 Jul;32(1):1-3
    Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:
    In this issue of Cancer Cell, Qu et al. describe the chromatin accessibility profiles of cutaneous T cell lymphoma, with dynamic assessments of response and resistance to histone deacetylase inhibitor therapy. Their "personal regulome" analysis framework reveals chromatin features that may be predictive of clinical response to epigenetic therapy. Read More

    Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of Sézary T lymphoma: a transcriptomic approach.
    Arch Dermatol Res 2017 Jul 10. Epub 2017 Jul 10.
    Aix Marseille Université, INSERM UMR_S 1090, Technological Advances for Genomics and Clinics, 13288, Marseille-Luminy, France.
    SAHA (vorinostat) is a histone deacetylase inhibitor approved by the USA Food and Drug Administration (FDA) for treating advanced refractory cutaneous T cell lymphomas. As SAHA alters the expression of many genes under control of the Sp1 transcription factor, we examined the effect of its association with the FDA-approved anticancer antibiotic Mithramycin A (MTR, plicamycin), a competitive inhibitor of Sp1 binding to DNA. Sézary syndrome (SS) cells, expanded ex vivo from peripheral blood mononuclear cells of 4 patients, were tested for their sensitivity to the drugs regarding cytotoxicity and differential responsive gene expression. Read More

    Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).
    Blood 2017 Jul 10. Epub 2017 Jul 10.
    Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States;
    Cutaneous T cell lymphoma (CTCL) is an incurable non-Hodgkin lymphoma of the skin-homing T cell. In early stage disease, lesions are limited to the skin, but in later stage disease, the tumor cells can escape into the blood, the lymph nodes, and at times the visceral organs. To clarify the genomic basis of CTCL, we performed genomic analysis of 220 CTCLs. Read More

    Syringotropic Mycosis Fungoides: A Rare Form of Cutaneous T-cell Lymphoma Enabling a Histopathologic "Sigh of Relief."
    Am J Dermatopathol 2017 May 18. Epub 2017 May 18.
    Departments of *Internal Medicine, and †Dermatology, UC Irvine Health, Irvine, CA.
    Syringotropic mycosis fungoides (STMF) is a very rare variant of cutaneous T-cell lymphoma. It follows a much milder disease course than its clinically indistinguishable adnexal counterpart, folliculotropic mycosis fungoides (FMF). We report a case of a 36-year-old man who presented with erythematous, studded papules and plaques on the left upper extremity and right anterior thigh diagnosed as mycosis fungoides (MF) Stage 1A on initial superficial shave biopsy. Read More

    Eruptive Seborrheic Keratoses Restricted to Plaque/Patch-Stage Mycosis Fungoides.
    Case Rep Dermatol 2017 May-Aug;9(2):35-39. Epub 2017 Jun 8.
    Department of Dermatology, CHU Sart Tilman, University of Liège, Liège, Belgium.
    Eruptive seborrheic keratoses (ESK) are rare in dermatology. They are usually inflammatory in nature and may be encountered as Leser-Trélat sign. ESK may also be simultaneously observed with hepatic angiomas, chemotherapy, segmental neurofibromatosis, HIV or erythrodermic pityriasis rubra pilaris, psoriasis, and drug eruption. Read More

    Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma.
    Int J Dermatol 2017 Jul 7. Epub 2017 Jul 7.
    Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
    Background: Second hematologic cancers in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) are well documented and include Hodgkin lymphoma, therapy-related acute myeloid leukemia/myelodysplastic syndromes, and transformation to diffuse large B-cell lymphoma. Although cutaneous T-cell lymphoma (CTCL) has been reported in patients with CLL, the incidence and comparison to expected rates are unknown. We evaluated the incidence of CTCL among patients with CLL or other non-Hodgkin lymphoma (NHL) subtypes using data from the Surveillance, Epidemiology, and End Results (SEER) Program. Read More

    Acral angiokeratoma-like pseudolymphoma in a middle-aged woman.
    J Cutan Pathol 2017 Jul 4. Epub 2017 Jul 4.
    Dermatology Service, Department of Medicine, New York, NY, USA.
    Acral angiokeratoma-like pseudolymphoma is a rare type of pseudolymphoma presenting as dark-red papules on the hand or foot. We describe a 59 year old woman who presented with an unusual unilateral, clustered aggregate of scaly violaceous papules on the toe with an indolent course. Skin biopsy showed a prominent vascular proliferation associated with a dermal infiltrate of monoclonally rearranged T-follicular helper phenotype T-cells, in keeping with CD4+ small/medium T-cell lymphoproliferative disorder (SMPTC-LPD). Read More

    A novel BLK-induced tumor model.
    Tumour Biol 2017 Jul;39(7):1010428317714196
    1 Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
    B-lymphoid tyrosine kinase (BLK) is a non-receptor tyrosine kinase belonging to the SRC family kinases. BLK is known to be functionally involved in B-cell receptor signaling and B-cell development. New evidence suggests that B-lymphoid tyrosine kinase is ectopically expressed and is a putative oncogene in cutaneous T-cell lymphoma and other T-cell malignancies. Read More

    Characterization of a novel canine T-cell line established from a dog with cutaneous T-cell lymphoma.
    J Dermatol Sci 2017 Jun 27. Epub 2017 Jun 27.
    Department of Veterinary Medicine, Faculty of Applied Biological Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan. Electronic address:

    Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
    Int J Hematol 2017 Jun 29. Epub 2017 Jun 29.
    Celgene K.K., Tokyo, Japan.
    This phase I/II multicenter study evaluated romidepsin treatment in Japanese patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). Patients aged ≥20 years received romidepsin via a 4-h intravenous infusion on days 1, 8, and 15 of each 28-day cycle. Phase I used a 3 + 3 design to identify any dose-limiting toxicity (DLT) for regimens of romidepsin 9 and 14 mg/m(2). Read More

    Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome.
    Clin Lymphoma Myeloma Leuk 2017 Jun 24. Epub 2017 Jun 24.
    Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT.
    Background: Management of mycosis fungoides and Sézary syndrome (MF/SS) is complex, and randomized evidence to guide treatment is lacking. The institutional treatment volumes for MF/SS might vary widely nationally and influence patient survival.

    Patients And Methods: Using the National Cancer Database, we identified patients with a diagnosis of MF/SS from 2004 to 2011 in the United States who had received treatment at a reporting facility. Read More

    Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
    Ann Diagn Pathol 2017 Jun 10;28:54-59. Epub 2017 Feb 10.
    Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY 10065, USA. Electronic address:
    Background: Negative immunoregulatory checkpoints impede effective immune responses to tumor and reduce the action of anticancer agents. One such example is programmed death marker-1 (PD-1), an inhibitory signaling receptor expressed on activated and regulatory T-cells. PD-1 expression was reported in a few reports, but the expression profile of PD-1 and mycosis fungoides (MF) remains largely to be characterized. Read More

    [Mycosis fungoides in a heart transplant recipient].
    Ann Dermatol Venereol 2017 Jun 22. Epub 2017 Jun 22.
    Service de dermatologie, groupe hospitalier du Havre, hôpital J.-Monod, BP 24, 76083 Le Havre, France.
    Background: Skin cancer occurs frequently in organ transplant patients as a result of induced immunosuppression. Most cases involve carcinomas or B-cell lymphomas induced by the Epstein Barr virus (EBV). Cutaneous T-cell lymphomas remain rare. Read More

    Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database.
    J Am Acad Dermatol 2017 Jun 20. Epub 2017 Jun 20.
    Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. Electronic address:
    Background: Studies have shown contradictory results regarding the survival outcomes among white, African American, and Asian patients with mycosis fungoides (MF).

    Objective: To evaluate the survival outcomes among white, African American, and Asian patients with MF and to determine other prognostic factors of the disease.

    Methods: The US National Cancer Database was used to identify patients with histologically confirmed MF from 2004 to 2014. Read More

    Erythema multiforme-like lesions in primary cutaneous aggressive cytotoxic epidermotropic CD8+ T-cell lymphoma: A diagnostic and therapeutic challenge.
    J Cutan Pathol 2017 Jun 23. Epub 2017 Jun 23.
    Dermatologic Clinic, University of Milan, Milan, Italy.
    Primary cutaneous aggressive cytotoxic epidermotropic CD8+ T-cell lymphoma is an extremely rare, rapidly progressing, cutaneous lymphoma, with frequent systemic involvement and poor prognosis, that still represents a diagnostic and therapeutic challenge, especially in the early stage. Herein, we report a case of an elderly woman with a fulminant course, who at onset presented with clinical and pathological features mimicking erythema multiforme (EM) and treated with cyclosporine that led to rapid deterioration with fatal outcome 6 months after disease onset. Histopathology showed a lichenoid, epidermotropic and nodular, angiocentric, dermal and subcutaneous infiltrate of sF1, CD8+, CD45RA+ small to medium-sized atypical lymphoid cells, which strongly expressed cytotoxic markers. Read More

    The discovery and development of romidepsin for the treatment of T-cell lymphoma.
    Expert Opin Drug Discov 2017 Aug 22;12(8):859-873. Epub 2017 Jun 22.
    b Department of Hematology , Medical University of Lodz , Lodz , Poland.
    Introduction: Romidepsin is a potent and selective inhibitor of histone deacetylases (HDCAi). It is also the only bicyclic inhibitor to undergo clinical assessment and is considered a promising drug for the treatment of T-cell lymphomas. The cellular action of romidepsin results in enhanced histone acetylation, as well as the acetylation of other nuclear or cytoplasmic proteins, influencing cell cycle, apoptosis, and angiogenesis. Read More

    Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators.
    Oncoimmunology 2017 17;6(5):e1306618. Epub 2017 Mar 17.
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Cutaneous T-Cell Lymphomas (CTCL) are rare, but potentially devastating malignancies, whose pathogenesis remains poorly elucidated. Unfortunately, currently it is not possible to predict based on the available criteria in which patients the cancer will progress and which patients will experience an indolent disease course. Furthermore, at early stages this malignancy often masquerades as psoriasis, chronic eczema or other benign inflammatory dermatoses. Read More

    Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series.
    J Dermatolog Treat 2017 Mar 2:1-3. Epub 2017 Mar 2.
    b Department of Dermatology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Objective: To demonstrate the clinical efficacy of topical 5% imiquimod for mycosis fungoides (MF) tumors.

    Background: Treatment of tumor-stage MF represents a therapeutic challenge because of a limited number of effective topical therapies. Single tumors can be treated with localized radiation but may recur. Read More

    8-methoxypsoralen reduces AKT phosphorylation, induces intrinsic and extrinsic apoptotic pathways, and suppresses cell growth of SK-N-AS neuroblastoma and SW620 metastatic colon cancer cells.
    J Ethnopharmacol 2017 Jul 13;207:19-29. Epub 2017 Jun 13.
    Department of Virology and Immunology, Maria Curie-Sklodowska University, Lublin, Poland. Electronic address:
    Ethnopharmacological Relevance: 8-methoxypsoralen (8-MOP) is a furanocoumarin and an active compound of a traditional Egyptian medicinal plant Ammi majus L, whose juice/fruit has been used for many years in folk phototherapy for the treatment of vitiligo or a hyperproliferative skin disorder, psoriasis. 8-MOP together with UVA light is also used as an anticancer drug for the treatment of cutaneous T-cell lymphoma. However, furanocoumarins exert anticancer activity even without UV irradiation. Read More

    Myxoid variant of primary cutaneous anaplastic large cell lymphoma: First 2 cases.
    J Cutan Pathol 2017 Jun 19. Epub 2017 Jun 19.
    Department of Dermatology, Los Angeles Medical Center (LAMC), Southern California Kaiser Permanente, Los Angeles, California.
    Anaplastic large cell lymphoma (ALCL) is a CD30+ T-cell non-Hodgkin lymphoma with 2 main clinical presentations: primary cutaneous ALCL (pcALCL) and systemic ALCL (sALCL). While rare cases of myxoid sALCL have been reported, there are no previous cases of myxoid pcALCL reported. We present 2 unusual cases of pcALCL showing prominent collections of dermal mucin closely intermingling with the anaplastic lymphocytes. Read More

    Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.
    Cancer Cell 2017 Jul 15;32(1):27-41.e4. Epub 2017 Jun 15.
    Center for Personal Dynamic Regulomes and Program in Epithelial Biology, Stanford University School of Medicine, CCSR 2155c, 269 Campus Drive, Stanford, CA 94305-5168, USA; Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address:
    Here, we define the landscape and dynamics of active regulatory DNA in cutaneous T cell lymphoma (CTCL) by ATAC-seq. Analysis of 111 human CTCL and control samples revealed extensive chromatin signatures that distinguished leukemic, host, and normal CD4(+) T cells. We identify three dominant patterns of transcription factor (TF) activation that drive leukemia regulomes, as well as TF deactivations that alter host T cells in CTCL patients. Read More

    Gamma-delta (γδ) T-cell lymphoma - another case unclassifiable by World Health Organization classification: a case report.
    J Med Case Rep 2017 Jun 19;11(1):163. Epub 2017 Jun 19.
    Division of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY, 11212, USA.
    Background: We present a case of gamma-delta T-cell lymphoma that does not fit the current World Health Organization classifications.

    Case Presentation: A 74-year-old Caribbean-American woman presented with lymphocytosis, pruritus, and non-drenching night sweats. Bone marrow and peripheral blood analyses both confirmed the diagnosis of gamma-delta T-cell lymphoma. Read More

    Tissue and serum lipidome shows altered lipid composition with diagnostic potential in mycosis fungoides.
    Oncotarget 2017 May 26. Epub 2017 May 26.
    Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China.
    Mycosis fungoides (MF) is the most common type of cutaneous T cell lymphoma. In this study, we used matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FTICR-MS) to perform lipidomic profiling of 5 MF tissue samples and 44 serum samples (22 from MF patients and 22 from control subjects). Multivariate statistical analysis of the mass spectral data showed that MF tissues had altered levels of seven lipids and MF sera had altered levels of twelve. Read More

    Associated Hematolymphoid Malignancies in Patients With Lymphomatoid Papulosis: A Canadian Retrospective Study.
    J Cutan Med Surg 2017 Jun 1:1203475417716366. Epub 2017 Jun 1.
    1 Division of Dermatology, University of Toronto, Toronto, ON, Canada.
    Background: Lymphomatoid papulosis is one of the primary cutaneous CD30+ T-cell lymphoproliferative disorders. Although considered a benign disease, lymphomatoid papulosis has been associated potentially with an increased risk of secondary hematolymphoid malignancies.

    Objective: The aim of this study was to assess the clinical characteristics and histologic subtypes of lymphomatoid papulosis, identify the prevalence and types of secondary hematolymphoid malignancies, and determine the potential risk factors for development of these hematolymphoid malignancies. Read More

    Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome).
    Case Rep Dermatol 2017 Jan-Apr;9(1):74-79. Epub 2017 Mar 21.
    aDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.
    Angioimmunoblastic T-cell lymphoma (AITCL) is a rare, aggressive lymphoma which derives from follicular helper T cells, commonly affecting the elderly population. It accounts for 2% of all non-Hodgkin lymphomas, with a reported 5-year overall survival rate of less than 30%. Very often, the clinical picture of AITCL encompasses systemic symptoms such as generalized lymphadenopathy, hepatosplenomegaly, skin rash, anemia, and polyclonal hypergammaglobulinemia. Read More

    ATF3 repression of BCL-XL determines apoptotic sensitivity toHDAC inhibitors across tumour types.
    Clin Cancer Res 2017 Jun 13. Epub 2017 Jun 13.
    Olivia Newton-John Cancer Research Institute
    Purpose: Histone deacetylase inhibitors (HDACi) are epigenome-targeting small molecules approved for the treatment of cutaneous T cell lymphoma and multiple myeloma. They have also demonstrated clinical activity in AML, non-small cell lung cancer and estrogen receptor-positive breast cancer, and trials are underway assessing their activity in combination regimens including immunotherpy.  However, there is currently no clear strategy to reliably predict HDACi sensitivity. Read More

    [Granulomatous reaction pattern of the skin : Interstitial granulomatous dermatitis - lymphoma - vasculitis].
    Hautarzt 2017 Jul;68(7):553-559
    Konsultations- und Referenzzentrum für Vaskulitis-Diagnostik, MVZ am Marienkrankenhaus gGmbH, Hamburg, Deutschland.
    A particular diagnostic situation in the classification of a granulomatous dermatitis results when no circumscribed granulomas but instead a diffuse interstitial histiocytic inflammatory infiltrate, a granulomatous vasculitis or a neoplastic lymphocytic infiltrate is found. Interstitial granulomatous dermatitis was originally described in patients with arthritis. Later, it was recognized that there are also associations with other usually immunological diseases. Read More

    Primary Cutaneous CD4(+) Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series.
    J Cutan Med Surg 2017 Jun 1:1203475417715209. Epub 2017 Jun 1.
    1 Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy.
    Background: Primary cutaneous CD4(+) small/medium T-cell lymphoproliferative disorder (CD4(+) PCSM-LPD) is defined by a predominance of small- to medium-sized CD4(+) pleomorphic T cells and a favorable clinical course.

    Objective: We performed a retrospective analysis of 6 patients with CD4(+) PCSM-LPD and reviewed the literature to address questions about its diagnosis, treatment, and prognosis.

    Methods: Patients were 3 men and 3 women with a median age of 50 years. Read More

    Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
    Lancet 2017 06 6. Epub 2017 Jun 6.
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Background: Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of life. Present systemic therapies rarely provide reliable and durable responses. We aimed to assess efficacy and safety of brentuximab vedotin versus conventional therapy for previously treated patients with CD30-positive cutaneous T-cell lymphomas. Read More

    VEGF protein expression is associated with a poor prognosis in cutaneous extranodal NK/T-cell lymphoma patients.
    Br J Dermatol 2017 Jun 9. Epub 2017 Jun 9.
    Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
    Vascular endothelial growth factor (VEGF) can stimulate angiogenesis and lymphangiogenesis, which are crucial processes in the growth and metastasis of tumour cells.(1,2) The immunohistochemical status of VEGF protein expression in tumour tissue of extranodal NK/T-cell lymphoma (ENKTL) has not yet been evaluated. Herein, we investigated VEGF protein expression, as well as its prognostic value in cutaneous ENKTL patients. Read More

    Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues.
    Allergy 2017 Jun 9. Epub 2017 Jun 9.
    The Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.
    Background: Atopic dermatitis (AD) is characterized by robust immune activation. Various T-cell subsets, including Th2/Th22 cells, are increased in lesional and nonlesional skin. However, there is conflicting literature on the diversity of the T-cell receptor (TCR) repertoire in lesional AD, and its relation to nonlesional skin remains unclear. Read More

    Increased Interleukin-19 Expression in Cutaneous T-Cell Lymphoma and Atopic Dermatitis.
    Acta Derm Venereol 2017 Jun 9. Epub 2017 Jun 9.
    Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
    Interleukin-19 (IL-19), a pro-inflammatory cytokine known to stimulate the production of T helper type 2 (Th2) cytokines, is induced by IL-17A and highly expressed in the lesional skin of psoriasis and atopic dermatitis (AD). This aim of this study was to investigate whether IL-19 is involved in cutaneous T-cell lym-phoma (CTCL) and AD. IL-19 levels were significantly higher in the sera of patients with AD and those with advanced-stage CTCL than in normal controls, correlating significantly with clinical disease markers. Read More

    CD4(+)CD26(-) lymphocytes are useful to assess blood involvement and define B ratings in cutaneous T cell lymphoma.
    Leuk Lymphoma 2017 Jun 9:1-10. Epub 2017 Jun 9.
    b Drexel University College of Medicine , Philadelphia , PA , USA.
    Bernengo et al. reported that >30% CD4(+)CD26(-) lymphocytes detect blood involvement in patients with mycosis fungoides (MF) and Sézary syndrome. In addition, the ISCL/EORTC suggested that this threshold might serve as a criterion for the B2 blood rating for staging. Read More

    BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
    Arch Dermatol Res 2017 Aug 7;309(6):491-497. Epub 2017 Jun 7.
    Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
    Bromodomain and external domain (BET) proteins regulate cell growth, proliferation, cell cycle, and differentiation in various cancers. Therefore, they have emerged as interesting targets. The effect of BET inhibitor on cutaneous T-cell lymphoma (CTCL), however, is yet to be known. Read More

    1 OF 223